PMID- 34465514
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20220531
IS  - 1477-2566 (Electronic)
IS  - 1465-3249 (Linking)
VI  - 23
IP  - 11
DP  - 2021 Nov
TI  - Umbilical cord-derived mesenchymal stem cells promote myeloid-derived suppressor 
      cell enrichment by secreting CXCL1 to prevent graft-versus-host disease after 
      hematopoietic stem cell transplantation.
PG  - 996-1006
LID - S1465-3249(21)00744-1 [pii]
LID - 10.1016/j.jcyt.2021.07.009 [doi]
AB  - BACKGROUND AIMS: Human mesenchymal stem cells (MSCs) from various tissues have 
      emerged as attractive candidates for the prevention and treatment of 
      graft-versus-host disease (GVHD). However, the molecular machinery that defines 
      and channels the behavior of these cells remains poorly understood. METHODS: In 
      this study, the authors compared the efficacy of four tissue-derived MSC types in 
      controlling GVHD in a murine model and investigated their immunomodulatory 
      effects. RESULTS: Human umbilical cord-derived mesenchymal stem cells (hUCMSCs) 
      effectively decreased the incidence and severity of GVHD, which was mediated by 
      the enrichment of myeloid-derived suppressor cells in GVHD target tissues. RNA 
      sequencing results showed that hUCMSCs highly expressed CXCL1. CONCLUSIONS: These 
      results suggest a novel prophylactic application of hUCMSCs for controlling GVHD 
      after allogeneic hematopoietic stem cell transplantation.
CI  - Copyright (c) 2021 International Society for Cell & Gene Therapy. Published by 
      Elsevier Inc. All rights reserved.
FAU - Wang, Rui
AU  - Wang R
AD  - Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, 
      Burn and Combined Injury, Third Military Medical University (Army Medical 
      University), Chongqing, China.
FAU - Wang, Xiaoqi
AU  - Wang X
AD  - Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, 
      Burn and Combined Injury, Third Military Medical University (Army Medical 
      University), Chongqing, China.
FAU - Yang, Shijie
AU  - Yang S
AD  - Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, 
      Burn and Combined Injury, Third Military Medical University (Army Medical 
      University), Chongqing, China.
FAU - Xiao, Yunshuo
AU  - Xiao Y
AD  - Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, 
      Burn and Combined Injury, Third Military Medical University (Army Medical 
      University), Chongqing, China.
FAU - Jia, Yanhui
AU  - Jia Y
AD  - Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, 
      Burn and Combined Injury, Third Military Medical University (Army Medical 
      University), Chongqing, China.
FAU - Zhong, Jiangfan
AU  - Zhong J
AD  - Department of Cell Biology, College of Basic Medicine, Third Military Medical 
      University (Army Medical University), Chongqing, China.
FAU - Gao, Qiangguo
AU  - Gao Q
AD  - Herman Ostrow School of Dentistry, University of Southern California, Los 
      Angeles, California, USA. Electronic address: qiangguogao@163.com.
FAU - Zhang, Xi
AU  - Zhang X
AD  - Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, 
      Burn and Combined Injury, Third Military Medical University (Army Medical 
      University), Chongqing, China. Electronic address: zhangxxi@sina.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210829
PL  - England
TA  - Cytotherapy
JT  - Cytotherapy
JID - 100895309
RN  - 0 (CXCL1 protein, human)
RN  - 0 (Chemokine CXCL1)
SB  - IM
MH  - Animals
MH  - Chemokine CXCL1
MH  - *Graft vs Host Disease/prevention & control
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - *Mesenchymal Stem Cell Transplantation
MH  - *Mesenchymal Stem Cells
MH  - Mice
MH  - *Myeloid-Derived Suppressor Cells
MH  - Umbilical Cord
OTO - NOTNLM
OT  - cell therapy
OT  - chemokine
OT  - hematopoietic stem cell transplantation
OT  - immunosuppression
OT  - mesenchymal stem cell
COIS- Declaration of Competing Interest The authors have no commercial, proprietary or 
      financial interest in the products or companies described in this article.
EDAT- 2021/09/02 06:00
MHDA- 2021/10/29 06:00
CRDT- 2021/09/01 05:53
PHST- 2021/01/28 00:00 [received]
PHST- 2021/07/14 00:00 [revised]
PHST- 2021/07/15 00:00 [accepted]
PHST- 2021/09/02 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
PHST- 2021/09/01 05:53 [entrez]
AID - S1465-3249(21)00744-1 [pii]
AID - 10.1016/j.jcyt.2021.07.009 [doi]
PST - ppublish
SO  - Cytotherapy. 2021 Nov;23(11):996-1006. doi: 10.1016/j.jcyt.2021.07.009. Epub 2021 
      Aug 29.